National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines Updated

Flash Update Sent July 13, 2011

NCCN has published updates to the NCCN Guidelines for Thyroid Carcinoma. These NCCN Guidelines are currently available as Version 3.2011.

The discussion section of the NCCN Guidelines for Thyroid Carcinoma has been updated to correspond with the treatment algorithm.


Flash Update Sent April 26, 2011

NCCN has published updates to the NCCN Guidelines and the NCCN Drugs & Biologics Compendium (NCCN Compendium™) for Thyroid Carcinoma. These NCCN Guidelines are currently available as Version 2.2011.

  • Based on supporting data and recent FDA approval, vandetanib (category 2A) was added as an option for the treatment of recurrent or persistent medullary thyroid carcinoma for patients in the following settings:
    • Locoregional disease: Vandetanib was added as an option to consider for the treatment of unresectable symptomatic or progressive disease.
    • Symptomatic, distant metastases: Vandetanib was added as a treatment option.
    • Asymptomatic, distant metastases: Vandetanib was added as an option to consider for the treatment of progressive disease.
    • Disseminated symptomatic disease: Vandetanib was added as a treatment option.
  • A corresponding footnote "j" was added to vandetanib that states, "Only health care professionals and pharmacies certified through the vandetanib Risk Evaluation and Mitigation Strategy (REMS) program, a restricted distribution program, will be able to prescribe and dispense the drug."
  • Footnote "k" was revised as follows: "While not FDA approved for treatment of thyroid cancer, other commercially available small molecule kinase inhibitors (such as sorafenib or sunitinib) can be considered if clinical trials or vandetanib are not available or appropriate, or if the patient progresses on vandetanib."

 

NCCN has published updates to the NCCN Guidelines for Palliative Care. These NCCN Guidelines are currently available as Version 2.2011.

The discussion section of the NCCN Guidelines for Palliative Care has been updated to correspond with the algorithm.

For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved